0

Pharmacological Mechanisms in Alzheimer's Therapeutics

Erschienen am 29.10.2010, 1. Auflage 2007
160,49 €
(inkl. MwSt.)

Lieferbar innerhalb 1 - 2 Wochen

In den Warenkorb
Bibliografische Daten
ISBN/EAN: 9781441924469
Sprache: Englisch
Umfang: xx, 324 S., 35 s/w Illustr., 10 s/w Tab., 324 p. 3
Einband: kartoniertes Buch

Beschreibung

InhaltsangabeOverview of the Alzheimer's disease pathology and potential therapeutic targets.- Trial designs and outcomes to monitor novel therapeutics in alzheimer's disease.- The pharmacological treatment of Alzheimer's disease with cholinesterase inhibitors and memantine.- M1 Muscarinic Agonists.- Cholinergic Neurodegeneration in Alzheimer's Disease: Basis for Nerve Growth Factor Therapy.- The rationale for glutamatergic therapy in Alzheimer's disease.- Secretases as pharmacological targets in Alzheimer's disease.- Secretase as a Target for Alzheimer's Disease.- The Rationale for an Immunological Approach to Alzheimer's Therapeutics.- Neuroinflammation, Alzheimer Disease and Other Aging Disorders.- Non-steroidal anti-inflammatory drugs (NSAIDs) and derived A42-lowering molecules for treatment and prevention of Alzheimer's disease (AD).- The potential application of antioxidant agents in Alzheimer disease therapeutics.- Apolipoprotein E: a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease.- Tau Pathology as a Target In Alzheimer's Therapeutics.- Design of inhibitors of Amyloid-beta misfolding and aggregation for Alzheimer's Therapy.- Potential applications of glycosaminoglycan-related compounds in Alzheimer's disease.- Multifunctional Neuroprotective Drugs for the Treatment of Alzheimer's Disease.- Interpreting Clinical Studies of Putative Therapeutics for Alzheimer's disease.

Inhalt

Overview of the Alzheimer¿s disease pathology and potential therapeutic targets.- Trial designs and outcomes to monitor novel therapeutics in alzheimer¿s disease.- The pharmacological treatment of Alzheimer¿s disease with cholinesterase inhibitors and memantine.- M1 Muscarinic Agonists.- Cholinergic Neurodegeneration in Alzheimer¿s Disease: Basis for Nerve Growth Factor Therapy.- The rationale for glutamatergic therapy in Alzheimer¿s disease.- Secretases as pharmacological targets in Alzheimer¿s disease.- Secretase as a Target for Alzheimer¿s Disease.- The Rationale for an Immunological Approach to Alzheimer¿s Therapeutics.- Neuroinflammation, Alzheimer Disease and Other Aging Disorders.- Non-steroidal anti-inflammatory drugs (NSAIDs) and derived A42-lowering molecules for treatment and prevention of Alzheimer¿s disease (AD).- The potential application of antioxidant agents in Alzheimer disease therapeutics.- Apolipoprotein E: a potent gene-based therapeutic target for the treatment of sporadic Alzheimer¿s disease.- Tau Pathology as a Target In Alzheimer¿s Therapeutics.- Design of inhibitors of Amyloid-beta misfolding and aggregation for Alzheimer¿s Therapy.- Potential applications of glycosaminoglycan-related compounds in Alzheimer¿s disease.- Multifunctional Neuroprotective Drugs for the Treatment of Alzheimer''s Disease.- Interpreting Clinical Studies of Putative Therapeutics for Alzheimer¿s disease.